Harrow Health Inc. (HROW)
NASDAQ: HROW
· Real-Time Price · USD
24.21
-0.52 (-2.10%)
At close: May 06, 2025, 3:59 PM
24.50
1.20%
Pre-market: May 07, 2025, 07:16 AM EDT
-2.10% (1D)
| Bid | 24.5 |
| Market Cap | 888.15M |
| Revenue (ttm) | 199.61M |
| Net Income (ttm) | -17.48M |
| EPS (ttm) | -0.49 |
| PE Ratio (ttm) | -49.41 |
| Forward PE | 15.82 |
| Analyst | Strong Buy |
| Ask | 25.8 |
| Volume | 326,413 |
| Avg. Volume (20D) | 505,176 |
| Open | 24.29 |
| Previous Close | 24.73 |
| Day's Range | 23.84 - 24.65 |
| 52-Week Range | 10.08 - 59.23 |
| Beta | 0.41 |
About HROW
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HROW
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HROW stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Harrow Health Inc. is scheduled to release its earnings on May 8, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+0.8%
Harrow shares are trading higher following a Q4 ad...
Unlock content with
Pro Subscription
1 month ago
+15.69%
Harrow shares are trading higher on possible continued strength after the company issued Q4 and FY24 revenue guidance above estimates yesterday. HC Wainwright & Co. reiterated a Buy rating on the stock.
1 week ago · seekingalpha.com
What Recession? I'm Swimming In DividendsWhat Recession? I'm Swimming In Dividends
1 month ago · seekingalpha.com
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings RampHarrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and impro...
1 month ago · businesswire.com
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial ResultsNASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. ...
